Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1631-1633

  Robinson, Joan L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

CANADA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GESTATIONAL AGE; HUMAN; LETTER; MORTALITY; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CANADA; COHORT STUDIES; COST-BENEFIT ANALYSIS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES;

EID: 67650468178     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902993415     Document Type: Letter

References (4)

1. Lanctot KL, Masoud TS, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadianbased analysis. Curr Med Res Opin 2008;24:3223-37
2. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150-6
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7
4. Feltes TF, Cabalka AK, Meissner HC, et al. for the Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40